NIPH Clinical Trials Search

UMIN ID: UMIN000002031

Registered date:02/06/2009

Exploratory analysis of predictive and prognostic biomarkers in the randomized phase III study of FOLFOX plus bevacizumab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (WJOG4407GTR)

Basic Information

Recruitment status Complete: follow-up complete
Health condition(s) or Problem(s) studiedmetastatic colorectal cancer
Date of first enrollment2009/06/01
Target sample size200
Countries of recruitmentJapan
Study typeObservational


Primary Outcome1) To correlate micro vascular density (MVD) and expression of VEGF-A in the tumor specimens with response rates (RR), progression free survival (PFS) and over all survival (OS). 2) To correlate expressions of various genes and k-Ras gene status in the tumor specimens with RR, PFS and OS. 3) To correlate the values of angiogenesis-related growth factors in plasma with RR, PFS and OS. 4) To correlate the profiles of glycoconjugates in plasma with RR, PFS and OS.
Secondary OutcomeNot applicable

Key inclusion & exclusion criteria

Age minimum20years-old
Age maximum75years-old
GenderMale and Female
Include criteria
Exclude criteriaNot applicable

Related Information


public contact
Name Shinichiro Nakamura
Address Japan
Telephone 06-6633-7400
Affiliation West Japan Oncology Group WJOG datacenter
scientific contact
Name Junji Tsurutani
Address 377-2 Ohnohigashi, Osakasayama, Osaka 589-8511 Japan Japan
Telephone 072-366-022
Affiliation Kinki University School of Medicine Department of Medical Oncology